Spectral AI, Inc. reported its financial results for the third quarter of 2025, revealing a significant decline in revenue and an increase in net losses compared to the same period in the previous year. The company generated $3.8 million in research and development revenue for the three months ended September 30, 2025, a decrease of 53.6% from $8.2 million in the same quarter of 2024. For the nine-month period, revenue totaled $15.6 million, down 29.2% from $22.0 million in 2024. The decline in revenue is attributed to reduced research and development activities as the company approached its De Novo submission under the Biomedical Advanced Research and Development Authority (BARDA) contract.
The company's net loss for the third quarter was $3.6 million, compared to a loss of $1.5 million in the prior year, marking a 136% increase in losses. For the nine months ended September 30, 2025, the net loss was $8.6 million, up from $7.6 million in 2024. The increase in losses is primarily due to higher operating costs, which rose to $5.0 million in the third quarter, up 9% from $4.6 million in the same quarter of 2024. The company’s accumulated deficit also increased to $56.9 million as of September 30, 2025, compared to $48.2 million at the end of 2024.
In terms of operational developments, Spectral AI has made strides in its product offerings, particularly with its DeepView System, which focuses on predictive medical diagnostics for burn wounds. The company received UKCA marking for the DeepView System in February 2024 and filed a De Novo application with the FDA in June 2025. The company anticipates that the DeepView System will generate two primary revenue streams: a software as a service (SaaS) model and an imaging device component. The company has also secured substantial funding from government contracts, including a recent $150 million contract with BARDA, which includes an initial award of approximately $54.9 million.
As of September 30, 2025, Spectral AI reported total assets of $15.3 million, up from $12.1 million at the end of 2024, primarily due to increased cash reserves, which rose to $10.5 million from $5.2 million. The company’s liabilities also increased, totaling $23.5 million, compared to $19.3 million at the end of 2024. The increase in liabilities is attributed to higher accounts payable and accrued expenses. The company’s employee headcount has also seen changes, reflecting its strategic focus on advancing its product development and regulatory submissions.
Looking ahead, Spectral AI remains optimistic about its future prospects, bolstered by its government contracts and the anticipated commercialization of the DeepView System. The company believes it has sufficient working capital to fund operations for at least one year, supported by its recent financing activities, including a $7.6 million capital raise from a securities purchase agreement in October 2025. However, the company acknowledges the inherent risks associated with product development and regulatory approvals, which could impact its financial performance moving forward.
About Spectral AI, Inc.
Spectral AI, Inc. develops AI-powered diagnostic tools for wound assessment, focusing on burn and tissue healing indications. Its DeepView System uses multispectral imaging and proprietary algorithms to predict wound healing potential, aiding clinicians in early, accurate treatment decisions. The company targets hospitals, burn centers, and emergency rooms, leveraging government contracts and strategic partnerships to commercialize its innovative, non-invasive medical diagnostics.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.